Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 9/20 | 0.45 |
| ▸ | CA1 | P00915 | 9/20 | 0.45 |
| ▸ | CA2 | P00918 | 9/20 | 0.45 |
| ▸ | CA9 | Q16790 | 9/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532982 | 0.80 | MAPK1 (0.58) | PIK3CA | |
| SCHEMBL532890 | 0.80 | IKBKB (0.46) | CA12CA1CA2CA9TP53 | |
| SCHEMBL532623 | 0.78 | DCTPP1 (0.47) | CA12CA1CA2CA9TP53 | |
| SCHEMBL2253625 | 0.77 | TP53 (0.69) | CA12CA1CA2CA9TP53 | |
| SCHEMBL533516 | 0.77 | PDE4D (0.47) | CA12CA1CA2CA9TP53 | |
| SCHEMBL532390 | 0.76 | SMN1; SMN2 (0.53) | TP53 | |
| SCHEMBL532645 | 0.76 | PIK3CA (0.59) | PIK3CAJAK2KCNH2LOXL2 | |
| SCHEMBL533129 | 0.74 | PIK3CA (0.71) | CA12CA1CA2CA9PIK3CA | |
| SCHEMBL532199 | 0.71 | ALDH1A1 (0.61) | CA12CA1CA2CA9PIK3CA | |
| SCHEMBL532352 | 0.68 | PIK3CA (0.41) | CA12CA1CA2CA9PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414369-B1 | IMIDAZO[2,1-B][1,3,4]THIADIAZOLE DERIVATIVES | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-08-12 | — | — | EP | disclosed |
| US-8815918-B2 | Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-08-26 | — | — | US | disclosed |
| US-20120094996-A1 | Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-19 | — | — | US | disclosed |
| EP-2414369-A1 | IMIDAZO [2, 1-B][ 1, 3, 4]THIADIAZOLE DERIVATIVES | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010112874-A1 | IMIDAZO [2, 1-B] [ 1, 3, 4 ] THIADIAZOLE DERIVATIVES | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094996-A1 | Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives | PIK3CA, PI4KA, PIK3CD | CA12 4737/4885CA1 4225/4885CA2 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.